Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: HIV Treatment
November 29, 2022
Integrase strand transfer inhibitor (INSTI)-based regimens have become the top drug class due to their excellent efficacy and tolerability profiles as well as their very high barriers to resistance. Both US and EU guidelines now favor INSTI-based regimens as initial “recommended” regimens, which has driven a steady decline in the market share of protease inhibitor (PI)- and non-nucleoside reverse transcriptase (NNRTI)-based regimens in the first-line setting. PIs suffer from the requirement for co-administration with a pharmacokinetic boosting agent, which increases the risk of drug-drug interactions and adverse events, while NNRTIs suffer from low barriers to resistance. In the maintenance setting, the launches of Juluca, Dovato, and Cabenuva will further drive consolidation to INSTI-based regimens by offering patients the opportunity to simplify their treatment regimens from three drugs to two.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||HIV / AIDS|